Europe, the Middle East, and Africa Lancet and Pen Needles Market

Primarily, lancets & pen needles are two prominent, single-use medical tools that are widely utilised to manage diabetes, with monitoring of blood sugar & administering essential drugs.

Various drivers are impacting the greater demand & adoption of these tools in different regions, such as:

Globally increasing cases of diabetes, especially in higher population regions, including India & China, necessitate continuous blood glucose monitoring & often insulin self-administration. Gradually, a huge geriatric population & establishing healthcare infrastructure are increasingly shifting from hospital-based treatments to at-home patient care. This majorly leads to a rise in the retail & direct-to-consumer demand for disposable lancets & pen needles.

On the other hand, leading firms are heavily investing in technological innovations that enhance patient comfort & safety, including micro-needle technologies, like 4mm & 5mm pen needles. Alongside other advances, cover pain-minimizing designs, adjustable depth settings, & pressure-activated or auto-retractable safety lancets to mitigate needlestick injuries.

According to Towards Healthcare, Standard Pen Needles Market Size, Key Players with Dynamics and Insights, the global standard pen needles market size is expected to be worth around USD 3.31 billion by 2035, from USD 1.71 billion in 2025, growing at a CAGR of 6.84% during the forecast period from 2026 to 2035. A rise in the use of insulin pens & surging demand for self-administration methods propel overall market expansion. Moreover, many government bodies are unveiling initiatives & offering funding to foster early diagnosis & treatment of diabetes, which ultimately raises adoption & demand for pen needles across the diverse regions.

Emerging Digital Integration & Government Encouragement Spurs the Growth of Lancet & Pen Needles Market in Europe�

A key catalyst is the evolution of smart, connected disposable devices that enable patients to log their injections and glucose levels via digital health platforms, which raises treatment adherence. In addition, the European industry is expanding due to well-nurtured healthcare systems in the UK, Germany, & France, which elevates broader availability of these devices, led by government support that boosts robust diabetes education & care standards.

Eventually, widening technological breakthroughs & research activities are enforcing substantial growth of the respective market in Europe. This mainly encompasses.

• Higher application of extra thin-wall designs for pen needles, which allow a crucially higher flow rate for high-viscosity medications by keeping the outer diameter minuscule, like 31G to 32G gauges for near-painless injections.
• European manufacturers are putting efforts into meeting European occupational hazards and cross-contamination regulations. Whereas standard lancets are being substituted by safety & pressure-activated lancets. Particularly, the BD AutoShield Duo uses dual-ended automated shields to protectively conceal needles both before & after utilization.
• Major research activities are executing total path control vertical-drive technology, which ensures needles enter & withdraw in a seamless straight path to combat lateral friction & physical pain.

A wider Emphasis on Policies & GCC Investments, Lucrative Expansion of Private Providers Fuels the MEA Industry Progression.

The lancet & pen needles market in the Middle East & Africa has been bolstered due to the rising burden of non-communicable diseases, while governments are raising their initiatives. South Africa has embedded targeted policies to prevent the growing incidence of diabetes, with greater accessibility to devices.

Moreover, another significant driver is the involvement of high-income countries within the Gulf Cooperation Council (GCC), especially Saudi Arabia & the UAE, which are significantly funding chronic disease management landscapes.

Ongoing consistent growth of private healthcare providers, medical centers, & clinics in urban zones of MEA has massively simplified the supply chain for sterile medical disposables, impacting the respective market progression across the MEA.

Developing research efforts in the MEA are emphasizing digitization & clinical safety to bolster the upcoming advances in the lancet & pen needles market.

Very firstly, researchers of the MEA are assessing how digital tools, such as culturally adapted SMS reminders & remote patient monitoring, can enhance medication adherence in remote & underserved areas of sub-Saharan Africa.

Besides this, the latest studies have demonstrated a major technology gap in the Middle East and Southeast Asia about the low uptake of continuous glucose monitors (CGMs) & insulin pumps versus pen needles, which focuses on searching for localized solutions for better pediatric & adult care.

However, continuous incentives are promoting an evaluation of the clinical feasibility of smart injection pens & single-use safety lancets to reduce cross-contamination risks & needle-stick injuries across busy primary care centers.

Numerous robust key manufacturers are aiming to launch smart, IoT-enabled lancing & injection devices, which connect standard data from blood sampling & insulin delivery into cloud-based patient management platforms.

How will Prospective Diabetic Cases Impact the Lancet & Pen Needles Industry Across Europe & MEA in 2050?

In the surging prevalence of diabetes, lancets have the same importance as a reliable backup for calibrating & validating continuous glucose monitors or in instances of device failure. In resource-restricted settings & low-income areas across Africa & the Middle East, manual blood glucose monitoring by leveraging lancets & multi-dose insulin delivery by utilizing pen needles will be highly available & life-saving alternatives.

Recent Launches in Europe, the Middle East & Africa, Lancet and Pen Needles Market

• In June 2026, Ascensia Diabetes Care introduced CONTOURCOMFORT pen needles to reinforce its CONTOUR portfolio with a solution that optimizes the everyday injection experience.
• In February 2026, Medtronic commercially launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe.
• In August 2025, Trividia Health UK Limited rolled out the TRUEplus 5-Bevel Pen Needles in the United Kingdom.

Leading Players of Europe, the Middle East & Africa: Lancet and Pen Needles Market & Their Offerings

• Becton, Dickinson and Company (BD): A firm that specializes in safety-engineered medical devices, like the BD Ultra-Fine pen needles & auto-retractable AutoShield Duo safety lancets.
• Novo Nordisk A/S: This company is empowering the development of smart insulin delivery systems, producing precision-engineered pen needles, like NovoFine & NovoTwist, to boost patient comfort & adherence.
• Ypsomed Holding AG: This has been offering the production of customizable, easy-to-use pens & pen needles personalized for both patients & pharmaceutical partners.
• MTD (Medical Technology and Devices)/HTL-Strefa: It is known as one of the world's giant manufacturers of medical lancets & pen needles.
• B. Braun SE: This player facilitates diversity in injection & blood-drawing needles to lower healthcare expenditures while ensuring high-quality capillary testing & medication delivery.
• Owen Mumford Ltd: Its offerings cover comfort-driven safety lancets & auto-injection devices for diabetes management.
• HTL-STREFA S.A.: This is a major player in safety lancets & pen needles, that supplies public & private healthcare sectors across EMEA

Conclusion

Particularly in Europe, increased expansion of lancets & pen needles is mainly driven by ongoing higher healthcare investments, surging geriatric population, & emergence of stricter safety regulations. Whereas the MEA nations are bolstering their healthcare budgets, coupled with surging cases of non-communicable diseases, like diabetes, in the Gulf Cooperation Council (GCC) countries & South Africa, are impelling the overall market development. Europe & the MEA are widely putting efforts into the transformation of digital health solutions, such as smart injection pens, micro-needles, single-use safety lancets, etc.